Le Lézard
Classified in: Health, Business
Subjects: CCA, FVT

DaVita Inc. Schedules 1st Quarter 2018 Investor Conference Call


DENVER, April 17, 2018 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services in the United States and in 11 countries around the world, announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 3, 2018, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.

This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: 

Thursday, May 3, 2018
Starting at 5:00 p.m. EDT
Dial in number: 877-918-6630
International dial in: 517-308-9042
Webcast: investors.davita.com

When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay.

About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and DaVita Medical Group. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of Dec. 31, 2017, DaVita Kidney Care operated or provided administrative services at 2,510 outpatient dialysis centers located in the United States serving approximately 198,000 patients. The company also operated 237 outpatient dialysis centers located in 11 countries outside the United States. DaVita Medical Group manages and operates medical groups and affiliated physician networks in California, Colorado, Florida, Nevada, New Mexico, Pennsylvania and Washington in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. DaVita Medical Group's teammates, employed clinicians and affiliated clinicians provided care for approximately 1.7 million patients. For more information, please visit DaVita.com/About.

Contact Information
Investors:
Jim Gustafson
(310) 536-2585
[email protected]

DaVita logo. (PRNewsFoto/DaVita)

 

SOURCE DaVita Inc.


These press releases may also interest you

at 23:00
Tech Innovator Purba Majumder Recognized as One of North America's Top 100 Women Leaders in 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:30
Blue Owl Capital Hires Australia Future Fund's Deputy Chief Investment Officer Alicia Gregory
Blue Owl Capital Inc. ("Blue Owl") , a leading alternative asset manager, announced today the hiring of Alicia Gregory as a Managing Director based in Sydney.   Alicia brings over 25 years of investing experience with deep relationships and...

at 22:00
Zetrix/MYEG and MaiCapital Ink MoU to Launch Virtual Asset Funds
Zetrix Foundation and MY E.G. Services Berhad ("MYEG") signed a Memorandum of Understanding (MoU) with MaiCapital, a licensed virtual asset manager in Hong Kong, to collaborate on the launch of a virtual asset fund or Hong Kong virtual assets...

at 21:38
GRUPO ELEKTRA ANNOUNCES REVENUE OF Ps.44,562 MILLION AND EBITDA OF Ps.6,363 MILLION IN THE FIRST QUARTER OF 2024
Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA* Latibex: XEKT), Latin America's leading specialty retailer and financial services company, and the largest non-bank provider of...

at 21:30
UPDATE - O2Gold Signs Definitive Agreement for Acquisition of Quebec Gold Mining Exploration Property; Announces Private Placement
O2Gold Inc. (NEX: OTGO.H) ("O2Gold" or the "Company") is pleased to announce that it has entered into a share exchange agreement dated March 21, 2024 (the "Agreement") with Quebec Aur Ltd., a private Ontario corporation, (the "Target") and its...

at 21:27
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

More news about Business...


News published on and distributed by: